EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C172H265N43O51 |
| Net Charge | 0 |
| Average Mass | 3751.262 |
| Monoisotopic Mass | 3748.94646 |
| SMILES | CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cncn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O |
| InChI | InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1 |
| InChIKey | YSDQQAXHVYUZIW-QCIJIYAXSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Roles: | anti-obesity agent Any substance which is used to reduce or control weight. glucagon-like peptide-1 receptor agonist An agonist that binds to and activates glucagon-like peptide-1 (GLP-1) receptors. |
| Applications: | hypoglycemic agent A drug which lowers the blood glucose level. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. antiparkinson drug A drug used in the treatment of Parkinson's disease. antidepressant Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. antipsychotic agent Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| liraglutide (CHEBI:71193) has role anti-obesity agent (CHEBI:74518) |
| liraglutide (CHEBI:71193) has role antidepressant (CHEBI:35469) |
| liraglutide (CHEBI:71193) has role antiparkinson drug (CHEBI:48407) |
| liraglutide (CHEBI:71193) has role antipsychotic agent (CHEBI:35476) |
| liraglutide (CHEBI:71193) has role cardiovascular drug (CHEBI:35554) |
| liraglutide (CHEBI:71193) has role glucagon-like peptide-1 receptor agonist (CHEBI:71196) |
| liraglutide (CHEBI:71193) has role hypoglycemic agent (CHEBI:35526) |
| liraglutide (CHEBI:71193) has role neuroprotective agent (CHEBI:63726) |
| liraglutide (CHEBI:71193) is a lipopeptide (CHEBI:46895) |
| liraglutide (CHEBI:71193) is a polypeptide (CHEBI:15841) |
| IUPAC Name |
|---|
| N2-(L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl)-N6-(N-hexadecanoyl-L-γ-glutamyl)-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycine |
| INNs | Source |
|---|---|
| liraglutida | ChemIDplus |
| liraglutide | WHO MedNet |
| liraglutide | KEGG DRUG |
| liraglutidum | ChemIDplus |
| Synonyms | Source |
|---|---|
| Liraglutide (rdna origin) | ChEMBL |
| NN 2211 | ChemIDplus |
| NN-2211 | ChemIDplus |
| NN2211 | ChemIDplus |
| NN-9924 | ChEMBL |
| NN9924 | ChEMBL |
| Brand Names | Source |
|---|---|
| Liraglutide component of xultophy 100/3.6 | ChEMBL |
| Victoza | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| 4164 | DrugCentral |
| D06404 | KEGG DRUG |
| DB06655 | DrugBank |
| Liraglutide | Wikipedia |
| US2006160736 | Patent |
| WO2008011518 | Patent |
| Registry Numbers | Sources |
|---|---|
| Reaxys:10331362 | Reaxys |
| CAS:204656-20-2 | KEGG DRUG |
| CAS:204656-20-2 | ChemIDplus |
| Citations |
|---|